Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 5200 participants.

Also called NCT05105321

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 5,200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05105321
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT05105321. Randomized; triple masking; primary purpose prevention. Start 2021-12 (anticipated); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)
Acronym
CDPP
Intervention (Drug)
Berberine
Intervention (Behavioral)
Healthy lifestyle intervention
Lead sponsor
Tang Yida (class: other)
Collaborator
Chinese Society of Cardiology (class: other)

Record details

Record id
cardio:ct-nct05105321
Content hash
b03b419117e4f4d3eafe3f6b55f36c60b295cf0c372e0400892bc10b8c4379ee